Orexigen Therapeutics — JMP Securities Healthcare Conference 2011
25 slides from Orexigen Therapeutics's conference presentation, Sep 27, 2011

Slide 1: JMP Securities Healthcare Conference
JMP Securities Healthcare Conference JMP Securities Healthcare Conference September 28, 2011 September 28, 2011 Exhibit 99.1

Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expre

Slide 3: Orexigen Strategic Summary
Orexigen Strategic Summary Regulatory Path Clarified Obesity Unmet Need Orexigen Position Orexigen Strategic Summary Clear path to approval defined by FDA’s OND Clear path to approval defined by FDA’s OND Time, cost and probability of success make approval Time, cost and probability of success make

Slide 4: Experienced Management Team with a Strong Balance Sheet
Experienced Management Team with a Strong Balance Sheet End of Q2 Cash and Investments Balance of $69.7m Currently Low Operating Expense Base and No Debt Experienced Management Team with a Strong Balance Sheet Michael Narachi, President and CEO 20-Year Veteran of Amgen – Including: GM of Anemia Busi

Slide 5: Regulatory Update
Regulatory Update Orexigen Position Global Need

Slide 6: The Orexigen Story – Two Years of Successes and Setbacks
The Orexigen Story – Two Years of Successes and Setbacks, but a Clear Path to Approval Has Emerged Filed NDA NDA Accepted by FDA Results Published in The Lancet & Obesity Signed Takeda Partnership Positive Advisory Committee Meeting The Orexigen Story – Two Years of Successes and Setbacks, but a Cle

Slide 7: FDA Has Provided Guidance on Critical Elements for Feasible Trial
FDA Has Provided Guidance on Critical Elements for Feasible Trial FDA Has Provided Guidance on Critical Elements for Feasible Trial Goal of trial is to demonstrate that the risk of CV events is not unacceptably high Primary endpoint is major CV events (MACE = CV death, MI, stroke) Enrolled patient p

Slide 8: Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates
Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates Typical Phase 3 Trial Approach for Contrave CVOT* Trial Focus Enables Streamlined Approach and Drives Feasible Cost Estimates Comprehensive evaluation of efficacy and general safety Targeted clinical question allows focused

Slide 9: Probability of Success at Interim Analysis is High
Probability of Success at Interim Analysis is High Probability of Success at Interim Analysis is High Bupropion well characterized in >50M patients over >25 years – Large prospective patient registries (up to 10,000 patients) and examination of AERS have not identified evidence of increased clinical

Slide 10: Estimated Timing of Key Events That Could Deliver a 2014 Approval
Estimated Timing of Key Events That Could Deliver a 2014 Approval Development Milestone Estimated Time Estimated Timing of Key Events That Could Deliver a 2014 Approval Finalize Protocol Details and Begin CVOT 7-9 months Enroll and Accrue 87 CV Events for Interim Analysis 18-20 months Time to Prepar

Slide 11: Global Need
Regulatory Update Orexigen Position Global Need

Slide 12: Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm
Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm 16% 34% 43% Serious Disease Attributable to Obesity Treatment Options Needed Increase in Obesity Obesity Epidemic Plus Lack of Solutions Have Created a Perfect Storm T2DM, Driven by Obesity, Is an Epidemic in Adults in the U.S. May

Slide 13: World Wide Obesity Prevalence Projected to Increase Over the Next Decade
World Wide Obesity Prevalence Projected to Increase Over the Next Decade World Wide Obesity Prevalence Projected to Increase Over the Next Decade n= ~473M people n= ~473M people n= ~655M people n= ~655M people % Growth % Growth 81% 81% 17% 17% 38% 38% 20% 20% 41% 41% Region Region Source: EuroMonito

Slide 14: Orexigen Position
Regulatory Update Orexigen Position Global Need

Slide 15: Contrave Keys to Commercial Success
Contrave Keys to Commercial Success Blockbuster Market Size Market Growth Significant Unmet Need – Limited Competition Contrave: Differentiated Profile Takeda: Well Established and Resourced Majority of Obese are Untreated in an Environment of Limited Treatment Options Contrave Keys to Commercial Su

Slide 16: Typical Response to Weight Loss Therapy is not Uniform
Typical Response to Weight Loss Therapy is not Uniform COR-I Weight Loss Distribution (Contrave32) Typical Response to Weight Loss Therapy is not Uniform COR-I Weight Loss Distribution (Contrave32) - - - - N =471 N=471 for COR-I subjects treated with Contrave

Slide 17: Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response
Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response COR-I Weight Loss Distribution (Contrave32) Our Recommended Treatment Algorithm Focuses on Patients who Achieve a Meaningful Response Our Focus: Patients Who Lose 5% <5% weight loss N=471 for COR-I subjects tre

Slide 18: Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy
Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy Treatment Algorithm: Identify Early Responders for Continued Long-term Therapy Appropriate BMI Motivated to Adhere to Lifestyle Change Inadequate Response to Diet & Exercise Select Responders for Continued Treatment Reinf

Slide 19: Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss
Contrave Early Responders Go on to Achieve Substantial Long Term Weight Loss Weight Loss Distribution 0% - 5% Weight loss 10% - 15% Weight Loss Avg Wt Loss = 26.7 lbs >15% Wt Loss Avg Wt Loss = 43.9 lbs Weight Gain 5% - 10% Weight Loss Avg Wt Loss = 17.0 lbs Contrave Early Responders Go on to Achiev

Slide 20: Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters
Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Contrave32 N=1038 Proportion w/ 5% Wt Loss Wk 16 Contrave Responders Achieve Improvement across Multiple Cardiometabolic Parameters Improvement (Standardized Mean Change from Baseline) Placebo N=254 -11.3% -8.6% -9.5

Slide 21: Contrave: Well Characterized Safety Profile
Contrave: Well Characterized Safety Profile Delivers Safety Experience Consistent with 20+ Year History of Underlying Agents Known Areas of Focus for Development Program – CV Effects, Seizure, Psychiatric Effects, Creatinine General Safety Profile Established in >4500 Patients with Single Approval D

Slide 22: Takeda is the Ideal Partner for Contrave
Takeda is the Ideal Partner for Contrave SUCCESSFUL BRAND BUILDER Actos ~$3B in U.S. Sales in 2009 Prevacid ~$3B in U.S. Sales in 2009 SCALE Top 15 Pharma Significant U.S. Presence Primary Care Focus COMMITMENT TO OBESITY Partnership with Amylin Stated Strategy DOMAIN EXPERIENCE Leader in Cardiometa

Slide 23: Competitive Product Profile Attractive to Patients
Competitive Product Profile Attractive to Patients Women Dominate the Market No Addictive Concerns Responders Maintained Meaningful Weight Loss 73% Competitive Product Profile Attractive to Patients No Abuse Liability No DEA Limitations on Distribution Expected 73% Sources: Orexigen Quantitative Mar

Slide 24: Orexigen Strategic Summary
Orexigen Strategic Summary Regulatory Path Clarified Obesity Unmet Need Orexigen Position Orexigen Strategic Summary Clear path to approval defined by FDA’s OND Clear path to approval defined by FDA’s OND Time, cost and probability of success make approval Time, cost and probability of success make

Slide 25: Orexigen
ts OREXIGEN
Source: SEC EDGAR · 8-K filed Sep 27, 2011
More decks from Orexigen Therapeutics Inc
Corporate Update (January 2018)17 slides · Jan 19, 2018
Corporate Update (January 2018)21 slides · Jan 8, 2018
BIO Investor Forum 201732 slides · Oct 16, 2017
Cantor Fitzgerald Healthcare Conference 201736 slides · Sep 26, 2017
Corporate Update (March 2017)56 slides · Mar 8, 2017
Investor Conferences February 13-17, 201755 slides · Feb 9, 2017